Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.
End-stage liver disease due to hepatitis C virus infection (HCV) is the principal indication for liver transplantation. In the USA, over a third of available liver allografts are transplanted into recipients with chronic HCV infection. Reinfection of the graft is universal, but the impact of reinfection on short- and long-term liver function is highly variable. HCV infection in liver transplantation recipients is characterized by an accelerated fibrogenesis, with approximately a third of patients developing cirrhosis within 5 years of follow-up. HCV is associated with decreased patient and graft survival when compared with other indications of orthotopic liver transplantation. The mechanisms responsible for the accelerated liver damage in HCV-infected orthotopic liver transplantation recipients remain largely unknown.
Maluf
Daniel G
DG
Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA. dmaluf@mcvh-vcu.edu
Archer
Kellie J
KJ
Villamil
Federico
F
Stravitz
Richard Todd
RT
Mas
Valeria
V
D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D006085:Graft Survival; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D011237:Predictive Value of Tests; D012008:Recurrence; D013997:Time Factors; D014184:Transplantation, Homologous
D015415:Biomarkers